AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia

RecruitingPhase 4Ages 18 Years - anyAllCentre Hospitalier Universitaire de Nīmes
💬

In plain words

What the trial is, and whether it could suit you

Assess the impact of a strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology on the early optimization of initial antibiotic therapy for ventilator-associated pneumonia (VAP) (intervention), compared to a conventional strategy (control). A bicentric, parallel-group, randomized controlled trial. The primary assessment criterion is the proportion of early optimized antibiotic therapy within 24 hours of respiratory sampling.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adults (≥18 years) with VAP (mechanical ventilation and hospitalization ≥ 48 hours) and deep respiratory sample by mini BAL \< 12 hours. The diagnosis of pneumonia includes two clinical criteria among fever (≥38.3°C), purulent sputum or aspiration, hyperleukocytosis (\>12,000 WBC/mm³) or leukopenia (\<4,000 WBC/mm³), hypoxemia, auscultatory signs in the affected area, and a newly-appeared parenchymal infiltrate * Patient receiving initial probabilistic antibiotic therapy for VAP suspicion * Informed consent or emergency procedure * Patient affiliated with or beneficiary of a health insurance plan. Non inclusion Criteria: * Pregnancy * Congenital immunodeficiency; * HIV infection with the lymphocyte CD4 count below 200/mm3 or unknown in the last year; * Acute hematologic malignancy; * Neutropenia (\<1 leucocyte/mL or \< 0.5 neutrophil/mL); * Immunosuppressive drugs within the previous 30 days, including anti-cancer - Chemotherapy and anti-rejection drugs for organ/bone marrow transplant * Corticosteroids ≥ 20 mg/d of prednisone equivalent for more than 14 days * Known allergy to beta-lactams * Moribund patient or death expected from underlying disease during the current admission; * Patient deprived of liberty or under legal protection measure; * Participation in another interventional trial. Exclusion criteria : * mPCR non available
💊

What it tests

  • strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology
📍

Where

2 sites
CH ALES
Alès, France
CHU Nîmes
Nîmes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy